Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-178M | $-166M | $-161M | -54.1% | - | 106.6% |
| 2024 | $0M | $-94M | $-80M | $-70M | -31.2% | - | 16.1% |
| 2023 | $0M | $-75M | $-69M | $-56M | 45.3% | - | 87.9% |
| 2022 | $0M | $-37M | $-37M | $-44M | 43.4% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 36.91 | 74.59 | 94.31 | 177.53 |
| Research And Development | - | 30.43 | 64.88 | 79 | 153.35 |
| Selling General And Administration | - | 6.47 | 9.71 | 15.30 | 24.18 |
| Total Expenses | - | 36.91 | 74.59 | 94.31 | 177.53 |
| Operating Income | - | -36.91 | -74.59 | -94.31 | -177.53 |
| Total Operating Income As Reported | - | -36.91 | -74.59 | -94.31 | -177.53 |
| EBITDA | - | -36.91 | -74.59 | -94.31 | -177.53 |
| Normalized EBITDA | - | -36.91 | -74.59 | -94.31 | -177.53 |
| EBIT | - | -36.91 | -74.59 | -94.31 | -177.53 |
| Interest Income | - | 0 | 5.26 | 13.82 | 11.23 |
| Net Interest Income | - | 0 | 5.26 | 13.82 | 11.23 |
| Interest Income Non Operating | - | 0 | 5.26 | 13.82 | 11.23 |
| Net Non Operating Interest Income Expense | - | 0 | 5.26 | 13.82 | 11.23 |
| Pretax Income | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income From Continuing And Discontinued Operation | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income From Continuing Operation Net Minority Interest | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income Common Stockholders | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income Including Noncontrolling Interests | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Normalized Income | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Diluted NI Availto Com Stockholders | - | -36.91 | -69.33 | -80.49 | -166.31 |
| Basic Average Shares | - | 31.96 | 31.96 | 31.47 | - |
| Diluted Average Shares | - | 31.96 | 31.96 | 31.47 | - |
| General And Administrative Expense | - | 6.47 | 9.71 | 15.30 | 24.18 |
| Other Gand A | - | 6.47 | 9.71 | 15.30 | 24.18 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc.this co. | AVBP | $1.5B | - | 5.02 | -54.1% | - |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Sonida Senior Living, Inc. | SNDA | $1.6B |
| - |
| - |
| - |
| - |
| -22.19 |
| -142770.48 |
| 643445.5% |
| 96.78 |
| Vir Biotechnology, Inc. | VIR | $1.5B | - | 2.02 | -57.2% | - |
| PROCEPT BioRobotics Corporation | PRCT | $1.5B | -16.08 | 4.20 | -26.1% | -15.56 |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| STAAR Surgical Company | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| Peer Median | - | -17.28 | 4.26 | -41.5% | -8.97 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Apr has averaged the highest return (+14.1%); Mar the lowest (-12.8%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +11.8%Positive MonthJan 2026: +11.78% | +2.1%Positive MonthFeb 2026: +2.13% | +0.4%Neutral MonthMar 2026: +0.44% | +34.8%Positive MonthApr 2026: +34.76% | -2.6%Negative MonthMay 2026: -2.64% | +14.8%Positive MonthJun 2026: +14.77% | -14.2%Negative MonthJul 2026: -14.16% | +0.7%*Neutral MonthAug 2026: +0.67% | — | — | — | — |
| 2025 | +7.1%Positive MonthJan 2025: +7.13% | -17.3%Negative MonthFeb 2025: -17.27% | -21.7%Negative MonthMar 2025: -21.69% | +15.0%Positive MonthApr 2025: +14.98% | -0.0%Neutral MonthMay 2025: -0.05% | +2.4%Positive MonthJun 2025: +2.45% | -10.4%Negative MonthJul 2025: -10.38% | -2.0%Neutral MonthAug 2025: -2.00% | -3.5%Negative MonthSep 2025: -3.50% | +1.5%Neutral MonthOct 2025: +1.52% | +22.5%Positive MonthNov 2025: +22.48% | -12.3%Negative MonthDec 2025: -12.29% |
| 2024 | — | -0.0%Neutral MonthFeb 2024: -0.05% | -17.1%Negative MonthMar 2024: -17.08% | -7.5%Negative MonthApr 2024: -7.50% | +17.5%Positive MonthMay 2024: +17.49% | -4.4%Negative MonthJun 2024: -4.43% | +18.1%Positive MonthJul 2024: +18.06% | +22.1%Positive MonthAug 2024: +22.05% | -12.1%Negative MonthSep 2024: -12.08% | +24.9%Positive MonthOct 2024: +24.85% | +2.1%Positive MonthNov 2024: +2.11% | -11.1%Negative MonthDec 2024: -11.08% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 3 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
